pd 98059 has been researched along with pyrimidinones in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dayanand, KK; Gowda, DC; Norbury, CC; Thylur, RP; Wu, X | 1 |
Chang, CD; Chang, LH; Chao, MW; Chen, YY; Lai, MJ; Liou, JP; Pan, SL; Teng, CM; Tu, HJ | 1 |
2 other study(ies) available for pd 98059 and pyrimidinones
Article | Year |
---|---|
Small molecule-based inhibition of MEK1/2 proteins dampens inflammatory responses to malaria, reduces parasite load, and mitigates pathogenic outcomes.
Topics: Adaptive Immunity; Animals; Antimalarials; Bone Marrow Cells; Cells, Cultured; Coculture Techniques; Dendritic Cells; Female; Flavonoids; Immunity, Innate; Killer Cells, Natural; Malaria, Cerebral; Malaria, Falciparum; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice, Inbred C57BL; Parasite Load; Parasitemia; Phagocytosis; Plasmodium falciparum; Protein Kinase Inhibitors; Protozoan Proteins; Pyridones; Pyrimidinones; Survival Analysis | 2017 |
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epigenesis, Genetic; ErbB Receptors; Flavonoids; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2019 |